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Summary.-Monitoring the incidence of angiosarcoma of the liver (ASL) between
1974 and 1977 has led to the confirmation by a panel of pathologists of 7 new cases of
ASL in patients who had received intra-arterial Thorotrast forradiological investiga-
tions. A cluster of cases has appeared in and around Edinburgh where the use of
Thorotrast was pioneered in Britain in 1933-48, and a mortality study of 113 Edin-
burgh patients has confirmed a significant excess of liver-tumour deaths in recent
years. Deaths from cancers of the lung and breast, and from hepatic cirrhosis, were
also in excess, but the limitations of the death-certificate data are described in rela-
tion to the clinical and pathological findings. Thorotrast was also used in other
centres, and an increased incidence in Britain of liver tumours attributable to this
agent is indicated.
THE EMPLOYMENT MEDICAL ADVISORY
SERVICE (EMAS) has been monitoring the
incidence of angiosarcoma of the liver
(ASL) in Great Britain since 1974, when
the association between this tumour and
occupational exposure to vinyl chloride
became known. In a preliminary study of
deaths from ASL in Britain during 1963-73
(Baxter et al., 1977) which included a
search for earlier cases reported in the
literature, one case only was found in a
patient who had received Thorotrast.
This collodial suspension of thorium
dioxide was once used as a contrast
medium in radiographic studies, and many
such cases have been reported from other
countries. The monitoring ofdeaths during
1974-77 has revealed 7 new Thorotrast-
induced cases of ASL, including a cluster
in the Edinburgh area. Thorotrast was
first used in Britain in Edinburgh mainly
for cerebral angiography in neurosurgical
patients, and a series of Edinburgh
patients has been studied in detail. Certain
long-term complications have appeared,
including progressive loss of splenic func-
tion (Langlands & Williamson, 1967), an
increased incidence of thyroid disease
(Langlands & Hermann, 1967), chromo-
somal damage (Buckton et al., 1967;
Buckton & Langlands, 1973) and an
excess of deaths from malignant disease,
in particular cancer of the liver (Ascroft
& MacCabe, 1962; Boyd et al., 1968). The
purpose of the present paper is to update
the mortality figures for those patients in
this series who had received intra-arterial
Thorotrast for cerebral angiography, and
to draw attention to the recent appearance
of cases of ASL arising from the past use
ofThorotrast in Edinburgh and elsewhere.
METHODS
Anyiosarcoina.-Cases of ASL are identi-
fied by EMAS in collaboration with the
Office of Population Censuses and Surveys
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(England and Wales) and the General
Register Office (Scotland) by reviewing death
certificates with an underlying cause ofdeath
routinely coded according to the Interna-
tional Classification of Diseases, 8th Re-
vision, by the Registrar General's staff as
primary, secondary or unspecified liver
neoplasms (ICD Nos. 155.0, 155.1, 197.8,
211.5) and neoplasms ofunspecified nature of
the liver and biliary passages (230.5), and
haemangioma or lymphangioma (227). Cancer
registries in England and Wales also send
notifications for these cases, but this informa-
tion is known to be incomplete. Some cases of
ASL are notified directly to EMAS by histo-
pathologists. In addition, for the purposes of
the present study, any death certificates in
England and Wales in the above ICD
categories for 1974-77 which mentioned
Thorotrast were also sought; also, death
certificates coded under "surgical and medical
complications and mis-adventure in diag-
nostic procedures" (ICD No. E932) were
readily accessible for England and Wales in
1973-77, and these were examined for men-
tion of Thorotrast use. For all these recorded
cases of ASL and liver cancer associated with
Thorotrast, the hospital pathologists con-
cerned were invited to send histological
material from the tumour for review by a
panel of 3 histopathologists (P.P.A.,
R.N.M.M.S. and P.J.S.). whose method of
working has been described (Baxter et al.,
1977). Briefly, members review the material,
along with that from control cases dying
from other liver cancers, independently and
without knowledge of the original diagnoses
or medical histories. A history ofThorotrast
administration can be confirmed because
thorium dioxide is readily visible on light
microscopy as aggregates of refractile par-
ticles scattered throughout the interstitium
in tissue macrophages.
Mortality analysis. In 1978 identification
details of 113 Edinburgh patients who were
known: (a) to have received an injection of
intra-arterial Thorotrast for cerebral angio-
graphy, and (b) to be alive one year or more
afterwards were sent to the National Health
Service Central Registers for tracing. Four
patients (40%) could not be traced. With one
exception, the ages at injection were dis-
tributed between 5 and 64 years (see Boyd
et al., 1968). All but one of the patients had
undergone the procedure at some time during
1933-48, and the end of the mortality follow-
up was 31 December 1977. Because the study
population was small, the person-years at
risk were calculated separately for the periods
1933-45, 1946-55, 1956-65 and 1966-77, and
expected numbers ofdeaths were obtained by
applying the age and sex-specific mortality
rates for Scotland in 1941, 1951, 1961 and
1971 respectively (Registrar General for
Scotland, 1941, 1953, 1963, 1972). Five-year
age bands were used unless 10-year bands
only had been published. The analysis
spanned 4 revisions of the International
Classification of Diseases (5th to 8th re-
visions), but these revisions did not pose any
serious difficulty when expected values were
calculated only for those causes with 2 or
more deaths (excluding cerebral neoplasms
and cardiovascular disease). The study popu-
lation had been defined in 1963 and regis-
tered with the Medical Research Council
Clinical Effects of Radiation Research Unit,
Edinburgh. From time to time the records of
these patients were updated with the assist-
ance oftheirgeneral practitioners andhospital
consultants. For all cases with a diagnosis of
liver tumour histological material was sought
for submission to the panel.
Statistical tests were applied on the
assumption that the number of observed
deaths followed a Poisson distribution with a
mean equal to the number of expected
deaths; where the number ofobserved deaths
exceeded 15, the normal approximation to
the Poisson distribution was assumed and the
2-tailed x2 test was used. The unpaired t test
was used to comparethe volume ofThorotrast
received in sub-groups of patients.
RESULTS
Angiosarcoma
Thirty-five cases of ASL recorded
throughout Britain in 1963-77, including
all those in the Edinburgh series, were
agreed as ASL by the panel, and the last
places of residence for these also recorded
(see Figure). Further details of the non-
Thorotrast cases are described elsewhere
(Baxter et al., 1980). Eight cases had a
history of Thorotrast administration and
this was confirmed on microscopy; 6 of
these died in or near Edinburgh, forming
a cluster in this area. The other 2 were men
aged 46 and 62 who had undergone the
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Fia-.Last places ofresidence of cases ofASL
agreed by the Panel. (Note the cluster of
Thorotrast-associated cases in and near
Edinburgh.)
original diagnostic procedure in England
36 and 30 years before respectively. One
died in 1972, and the reason for the diag-
nostic procedure was stated to be an
injury to the blood vessels of the neck
sustained while working in a coal mine
(Asbury et al., 1974). He was missed in the
1963-73 survey even though a diagnosis
of ASL associated with Thorotrast had
been recorded, but the death certificate
had been coded under ICD No. 946: "late
effects of accidental injury-other acci-
dents". The other man died in 1977
(Underwood & Huck, 1978). For the period
1973-77, 2 death certificates for Eng-
land and Wales were found, for 1977,
with a diagnosis of primary liver cancer
andmentioningThorotrastadministration.
We confirmed the presence of Thorotrast
and the diagnosis ofliver-cell carcinoma in
both cases.
Mortality analysis
Fifty-four men and 55 women in the
Edinburgh series were available for study;
37 men and 39 women had died by the end
of 1977. The overall pattern of mortality
was the same for both sexes, and so, as the
numbers of deaths were small, the results
were pooled (Table I). The observed
TABLE I.-Person-years at risk, and ob-
served and expected deaths, for all cancers
and all causes in the Edinburgh series
No. ofdeaths
Person- ,-
years All cancers All causes
at ,
Age risk Obs. Exp. Obs. Exp.
< 15 41 0 0 0 0-1
15-24 229 0 0 2 0-6
25-34 463 1 0-1 5 1-2
35-44 659 1 0 5 10 2-4
45-54 653 9 1-4 18 5-2
55-64 464 8 2-3 24 8-7
>64 200 5 2-1 17 9-5
Total 2709 24* 6-4 76* 27-7
Obs./Exp. 3-8 2.7
*P < 0-001.
numbers ofdeaths from all cancers and all
causes were higher than expected in each
age group, and the mortality ratios for the
totals of deaths from these causes were
significantly raised, at 3-8 and 2-7 re-
spectively. It must be remembered that
these neurosurgical patients were sus-
pected or diagnosed to be suffering from
cerebral neoplasms or cerebrovascular
abnormalities, especially the latter, and
thus raised mortality in the follow-up
period would be expected for the total
deaths from all cancers and all causes,
irrespective of receiving Thorotrast. How-
ever, when these causes are excluded,
deaths from cancers of the lung, breast
and liver, and from hepatic cirrhosis, are
notable for their excess; among the non-
malignant diseases, only deaths from
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TABLE II. Observed and expected numbers
of deaths for those causes in excess in the
Edinburgh series
Cause of dleatlh
according to Nos of deatlhs
(leatli
certificate Males Females Obs. Exp.
Primary canieer:
Lung 7 0 7* 1-7
Breast 0 4 4* 0 6
Liver 3 3 6** 0.1
Cirrhosis ofliv-er 2 : 4** 0-1
Obs./
Exp.
4-1
6-7
60-0
40 0
*P<0-01.
** P < 0-001.
hepatic cirrhosis were in excess (Table II).
The remaining 7 deaths certified as cancer
(4.0 expected) comprised 3 brain tumours,
cancers of the pancreas, bladder, and
rectum; and lymphatic leukaemia. There
were no deaths attributed to bone sarcoma.
Blood disorders accounted for 3 deaths,
according to both the death certificates
and medical records. One male died from
lymphatic leukaemia (mentioned above),
and one female each from aplastic anaemia
and thrombocytopenia. The volume of
Thorotrast received and, in parentheses,
the interval between injection and the
onset of clinical symptoms in these
patients were, respectively, as follows:
30 ml (21 years), 70 ml (26 years) and
1]5 ml (14 years).
Clinical and pathological findings
Some clinical information was available
for most deaths. Necropsy details were
available in 19 (510%) male and 13 (33%)
female deaths. It was not known whether
a necropsy had been carried out in a third
of the male and female deaths, but for the
remainder no necropsy had been per-
formed.
Ltng cancer
Confirmatory necropsy details were
obtained for 3 of the 7 deaths certified as
primary cancer of the lung, but in 2 of the
remaining 4 the postmortem diagnosis
was primary cancer of the pancreas and of
the liver, respectively. In the latter case,
the pleura had been regarded as the
primary site before histological examina-
tion had been completed (Table III).
Clinical details for the 2 cases without a
necropsy indicated that a presumptive
diagnosis oflung cancer had been made.
Breast cancer
The diagnosis in the 4 deaths certified
as cancer of the breast had been made on
histological evidence during life, but in
none of these was there necropsy con-
firmation. The ages of these patients at
the time of injection of Thorotrast (and at
death) were as follows: 28 (55); 28 (56);
38 (56); and 45 (49) years.
Liver cancer and cirrhosis
All 6 deaths with an underlying cause
coded as primary cancer of the liver had
been confirmed at necropsy (Table III).
However, 3 of the 4 deaths coded as
cirrhosis of the liver had also been diag-
nosed as primary liver cancer at necropsy,
and 2 of the death certificates mentioned
this; no necropsy had been undertaken in
the 4th case, but a laparoscopy during life
had shown a suspected vascular tumour
of the liver. This attribution of cirrhosis
on the death certificate is probably likely
to occur in Thorotrast patients, because a
fibrotic appearance of the liver is a com-
mon feature with or without malignant
changes. Three more deaths had been mis-
leadingly classified, as well as one of the
deaths from cancer of the lung mentioned
above; necropsy or surgical biopsy had
shown the diagnosis to be primary tumour
of the liver, but the respective underlying
causes of death had been coded under
carcinoma of the rectum (though "carcin-
oma of the liver" was also mentioned),
multiple angiomas of the liver, and late
effect of accidental injury irradiation
(ASL was also mentioned).
Histological examination ofthe primary
liver tumours had not been made in 2
cases where a diagnosis of primary
carcinoma had been made at necropsy.
Histological material was therefore not
available for these 2 and could not be
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TABLE III.-Details of primary liver tumours in the Edinburgh series
according to death certificate in parentheses)
Diagnosis according
to death
certificate
Carcinoma (rectum)*
Carcinoma (liver)
Carcinoma (pleura)
Angioma (liver)
Cirrhosis
Carcinoma (liver)
Carcinoma (liver)
Carcinoma (liver)
Carcinoma (liver)
Cirrhosis
Carcinoma (liver)
Cirrhosis*
Irradiation accident
Histology according to:
Pathologist Panel
Bile ductt Bile duct
Bile duct§ Bile duct
Carcinoma
ASL
Carcinoma
Bile duct Bile duct
Bile duct Bile duct
Liver cell
Liver cell ASL
ASL ASL
ASL ASL
ASL ASL
ASL ASL
Sex
F
M
M
F
F
M
F
F
M
M
F
M
M
Age at
death
47
49
43
40
73
47
48
58
49
62
45
50
55
Years
since
investigation
24
25
22
18
29
25
35
37
28
33
30
35
30
(site of primary
Year
Dose of
(ml) death
25
24
75
34
14
78
45
20
36
38
38
25
32
1957
1959
1959
1963
1968
1970
1972
1972
1973
1975
1975
1977
1977
* Carcinoma ofliver mentioned.
t (Gardner & Ogilvie, 1959).
t ASL mentioned.
§ (Ellis, 1964).
traced for 2 other cases either. For the
remainder, the diagnoses ofthe Panel and
hospital pathologists agreed, except in
one case which the Panel regarded as ASL
and not a liver-cell carcinoma as originally
diagnosed.
Table III shows that deaths from ASL
secondary to thorium dioxide administra-
tion have emerged-after an interval of
28-35 years since the initial investigations.
The death certified as angioma ofthe liver
in 1963, anddiagnosed asASL atnecropsy,
was not discovered in the 1963-73 survey,
and may be regarded as the first recorded
case of ASL associated with Thorotrast in
Britain. In addition to the 5 confirmed
cases of ASL in Table III, another con-
firmed case died near Edinburgh in 1972
(Campbell & Webb, 1974) and should have
belonged to this series, but he was not
included when the original population had
been defined, because his medical records
did not mention that Thorotrast had been
used. This man died aged 69, 30 years after
the investigation, and the cause of death
established at necropsy and recorded on
thedeathcertificatewasASL. Surprisingly,
Thorotrast was mentioned on only 2
certificates for these 14 deaths from
primary tumours ofthe liver, and on none
of those for deaths from other causes.
Amount ofThorotrast administered
The volume of Thorotrast received was
known for all but 9 patients; the means
(and s.d.) were 26-1 (14.7) ml and 26-8
(16.7) ml for males and females respec-
tively. The mean volume for the patients
dying from primary tumours of the liver
(Table III) was 37-2 (19.4) ml compared
with 25-0 (13.8) ml for those dying from
other causes, a difference which was
statistically significant (P<0-02), but no
relationship is apparent between the
volume given and the years since the
investigation. No associations with the
volume received were discernible for any
of the other causes of death.
DISCUSSION
After intra-arterial injection, Thoro-
trast becomes permanently deposited in
the body, mainly in the reticuloendo-
thelial or mononuclear phagocytic cells of
the liver, spleen, marrow and lymph
nodes, where it emits radiation con-
tinuously over the patient's lifetime. The
main incentive for its use was the ex-
cellent radiographic contrast it provided
at a time when radiology and neuro-
surgery were in their infancy. Introduced
in 1928, the hazards of Thorotrast had
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become apparent by 1950, and its use in
Britain was curtailed; in no other centre
had it been used as much as in Edinburgh.
There is no reason to suppose that the
Edinburgh patients differed in any im-
portant respects from those who received
intra-arterial Thorotrast elsewhere in
Britain. AIn impression may have arisen
that Thorotrast-induced diseases are only
of historical importance, anid no longer to
be seen in clinical practice in Britain, but
our findings like, for example, those of a
recent epidemiological study in the United
States (Falk et al., 1979) indicate that liver
tumours, in particular ASL, are becoming
more commnon among Thorotrast patients
as follow-up continues. Clinicians should
be alert to this development, especially as
patients may not always provide a history
of receiving Thorotrast, though radio-
graphy of the abdomen reveals radio-
opaque deposits of thorium dioxide in the
liver, spleen and tributary lymph nodes in
most cases. Also Thorotrast was still being
used in Britain in the diagnosis of cerebral
abscesses until supplies were discontinued
in the 1 960s, and doubts have been raised
that it remains localized to the injection
site as has been previously supposed
(Lancet, 1977).
The largest series ofpatients studiedl are
from Portugal, Denmark and Germany
(Mole, 1978) where the use of intra-
arterial Thorotrast was much greater
than in Britain, and only recently have
sufficient numbers of deaths occurred in
the Edinburgh series to make comparisons
with these worth while. On the other hand,
unlike the other series, the follow-up of
the Edinburgh patients has been almost
complete. The main mortality findings
from the other series have been sum-
marized by Mole (1978): a definite excess
of deaths from liver tumours and leuk-
aemia, and probably also cancers of the
marrow and lymphoreticular tissue, but
the evidence for an increased risk of bone
sarcoma is equivocal; there was an excess
of deaths from cancer of the lung in the
Danish and Portuguese, but not in the
Glerman series.
.
In the present study there was an
overall excess of deaths from malignant
disease, and specifically from liver
tumours, which comprised 17%0 of all
deaths. Five of the 13 tumours were con-
firmed by the Panel as ASL, and 4 others
as bile-duct tumours, both types having
been shown to be more common than
liver-cell tumours in Thorotrast patients
(Da Silva Horta et al., 1974). ASL was
once regarded as being an almost specific
cancer of Thorotrast patients because of
its rarity in the general population; indeed,
it can be seen that the number of con-
firmed cases of AST, in the Edinburgh
series over the follow-up period was
greater than the annual average for the
whole of Great Britain. As in the Portu-
guese series (Da Silva Horta et al., 1974)
the mean volume of injected Thorotrast
was significantly higher among deaths
from liver cancer than those from other
causes, whereas the mean volume for all
patients in the 2 series was almost
identical.
The excess of deaths from cancer of the
lung accords with findings in the Portu-
guese and Danish series. Two of these
deaths were almost certainly wrongly
certified, but this does not invalidate the
statistical comparison of death-certificate
data with national rates suffering from the
same biases (Rose & Barker, 1978).
Thoron, a product of thorium decay, is
slowly released and excreted in the breath
of these patients, resulting in exposure of
the bronchial epithelium to alpha radia-
tion. The deaths occurred in males only,
and this could in part, perhaps, be ex-
plained by their greater cigarette con-
sumption, assuming that the study group
resembled the general population in this
respect; in 1948 the proportion of all male
adults in the United Kingdom who
smoked was 20% higher than in 1976, but
the proportion for females has shown
little change, so that there is lately little
difference between the 2 sexes, though
male smokers have always smoked sub-
stantially more (Capell, 1978). The excess
of certified deaths from cancer of the
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breast is not so readily explained, and is at
variance with the findings of the other
series. On the other hand, the 3 deaths
from haematological disorders are con-
sistent with the marrow irradiation effects
of Thorotrast (Johnson et al., 1977). The
absence of deaths from bone sarcoma in
the present small series is also not sur-
prising, as this is an uncommon finding
even in Thorotrast patients.
Thorotrast patients, like uranium
miners, radium dial painters and German
224-radium patients, have been inten-
sively studied for the knowledge they pro-
vide on the effects of internal oc-particle
emitters in man, and the findings are of
direct application in the radiological pro-
tection of plutonium and other radiation
workers (Medical Research Council, 1975)
The occurrence of one case of ASL in a
plutonium worker would be noteworthy
(Mole, 1976) but our findings show how
cases could be missed in occupational
mortality studies ifreliance is placed solely
on death-certificate data. Because death
certificates usually fail to mention Thoro-
trast, there is no ready means of monitor-
ing deaths associated with its past use, and
the finding of only 2 certified deaths from
Thorotrast-associated liver cell cancer in
England and Wales during 1974-77 is
therefore unlikely to reflect the true
incidence. Cases of ASL in Thorotrast
patients are more readily identifiable, as
the tumour is so rare, and for this reason
they stand out as marker tumours when
other deaths associated with Thorotrast
have been missed. Monitoring the inci-
dence of ASL has therefore alerted us to
the continuing effects of this long-recog-
nized iatrogenic hazard.
ADDENDUM
Two further Thorotrast patients noti-
fied as dying from ASL in England in 1978
have been agreed by the panel as ASL;
neither belonged to the Edinburgh series.
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